TCRXHealthcare · BiotechnologyThe 6 Wall Street analysts covering TScan Therapeutics, Inc. hold a median 12-month price target of $6 — +669.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores TScan Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (97): Sales and profits are climbing, and climbing faster than before.
Momentum (9): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TCRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +669.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 23 June 2026 | Needham | Reiterates | Buy | $6.00 |
| 23 June 2026 | Needham | Reiterates | Buy | — |
| 23 June 2026 | Wedbush | Reiterates | Outperform | $5.00 |
| 23 June 2026 | Wedbush | Reiterates | Outperform | — |
| 5 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Nov 2025 | BTIG | Downgrade | Neutral | — |
| 4 Nov 2025 | Needham | Maintains | Buy | — |
| 7 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 14 Mar 2025 | Morgan Stanley | Assumes | Overweight | $10 |
| 7 Mar 2025 | Barclays | Maintains | Overweight | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Mar 2025 | Needham | Maintains | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2024 | Needham | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2024 | Needham | Reiterates | Buy | — |
| 6 Nov 2024 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TCRX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 18% of US stocks
Cheaper than 85% of US stocks
Cheaper than 63% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TScan Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
TScan Therapeutics reported a Q2 loss of $0.23 per share, which was narrower than the Zacks Consensus Estimate of a $0.29 loss but compared with a $0.28 per share loss in the same quarter a year ago.
Why it matters — TCRX watchers would note how the company's quarterly results compare with analyst consensus and prior-year performance as a gauge of its financial trajectory.
TScan Therapeutics reported financial results for the three months ended June 30, 2026, and provided a corporate update. The update noted the first patient dosed in the Phase 3 ALLOHA-2 study with a topline readout expected mid-2028, shared positive initial data from Cohort C of the Phase 1 ALLOHA study validating its commercial-ready manufacturing process, and stated cash and cash equivalents fund operations into the second quarter of 2027.
Why it matters — The update provides TCRX watchers with key milestones on the clinical pipeline, manufacturing validation, and cash runway through the second quarter of 2027.
TScan Therapeutics announced that the first patient has been dosed in its pivotal Phase 3 ALLOHA-2 trial evaluating TSC-101 in patients with hematologic malignancies.
Why it matters — This marks the initiation of a pivotal trial for TScan's lead TCR-T therapy candidate, advancing it toward potential regulatory submission.
The 6 Wall Street analysts covering TScan Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering TScan Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TScan Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, TScan Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +669.7% from the last close, and Ticker Nerd's factor model ranks TScan Therapeutics, Inc. 37 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TScan Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
TScan Therapeutics, Inc. returned -55.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
TScan Therapeutics Inc. operates as a clinical-stage biotechnology company focused on the development of T-cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer.
The most recent item we track (Zacks Investment Research, 12 Aug 2026): "TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates". TScan Therapeutics reported a Q2 loss of $0.23 per share, which was narrower than the Zacks Consensus Estimate of a $0.29 loss but compared with a $0.28 per share loss in the same quarter a year ago.
TScan Therapeutics Inc. operates as a clinical-stage biotechnology company focused on the development of T-cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's primary function is to harness the power of the immune system to battle various forms of cancer through innovative TCR-T technology. By engineering T cells to recognize and attack tumor cells, TScan aims to provide novel treatment options for patients with unmet medical needs. TScan Therapeutics is particularly significant in the fields of oncology and immunotherapy, where it targets several types of malignancies, including solid tumors and hematological cancers. The biotech firm conducts extensive research and trials to advance its pipeline of therapeutic candidates, which could potentially revolutionize cancer treatment paradigms. With its headquarters located in Waltham, Massachusetts, TScan Therapeutics plays a vital role in the ongoing exploration and development of immune-oncology therapies, contributing to a greater understanding of T-cell engineering in combatting cancer.
CEO Dr. Gavin MacBeath Ph.D. · 138 employees · United States · https://www.tscan.com